Announcements Trials

Browse Landscape

Phase

Phase 2 4 Phase 1 3 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 7 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5 Prednisone 5 Androgen Antagonists 5 gallium 68 PSMA-11 4 enzalutamide 3 bicalutamide 3 Triptorelin Pamoate 3 Radiosurgery 3 Leuprolide 3 Goserelin 3 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3 abiraterone 2 Zoledronic Acid 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Mitoxantrone 2 Flutamide 2 Celecoxib 2 Abiraterone Acetate 2 satraplatin 1 relugolix 1 pertuzumab 1 nilutamide 1 maltodextrin 1 luprolide acetate gel depot 1 histrelin 1 genistein combined polysaccharide 1 fluciclovine F-18 1 darolutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Prostatic Neoplasms × abemaciclib × Clear all

NCT03706365 2026-04-24

CYCLONE 2

Eli Lilly and Company

Phase 2/3 Active not recruiting

393 enrolled 23 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡